Please ensure Javascript is enabled for purposes of website accessibility

Why Emergent BioSolutions Stock Is Tanking Today

By Brian Feroldi – Updated May 3, 2019 at 3:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares drop after the company reports first-quarter results that missed the mark.

What happened

In response to the company's report of first-quarter earnings, shares of Emergent BioSolutions (EBS 0.38%), a commercial-stage biotech focused on bioterrorism defense products, had dropped 10% as of 3:08 p.m. EDT on Friday.

So what

Here are the headline numbers from the company's first quarter:

  • Revenue jumped 62% to $190.6 million. The big jump is largely attributable to strong sales of NARCAN nasal spray, which is a recently acquired drug that treats overdoses.
  • Net loss was $26 million, or $0.51 per share.
  • Adjusted net loss was $6.8 million, or $0.13 per share. That figure was well behind the $0.09 in net income per share that analysts had estimated.
  • The company signed a new contract with the U.S. State Department valued at up to $100 million over 10 years.

Management also shared guidance for the upcoming quarter and full year:

  • Second-quarter revenue is expected to land between $200 million and $220 million. That's well short of the $254 million that Wall Street was expecting.
  • Full-year revenue is expected to be between $1.06 billion and $1.14 billion.
  • Full-year net income is forecast between $80 million and $110 million.
  • Full-year adjusted net income is expected to land between $150 million and $180 billion.
Colorful drugs on top of hundred dollar bills

Image source: Getty Images.

In addition to the first-quarter miss and weak second-quarter revenue guidance, Emergent BioSolutions was also called a strong sell by a research company today.

Add it all up, and it's no surprise to see the share price being punished today.

Now what

If management can deliver on the midpoint of its full-year guidance, then revenue and adjusted net income will grow by 41% and 36%, respectively. Those are numbers that should make any growth-focused investor smile.

However, management's first-quarter results and second-quarter guidance suggest that the bulk of the growth will not materialize until the back half of the year. That means that investors have some waiting to do before they get a better idea of whether or not the company will be able to deliver.

Brian Feroldi has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
EBS
$21.07 (0.38%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.